Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Ipamorelin | GHRP-2 |
|---|---|---|
| Class | Selective GH secretagogue | GH secretagogue |
| Research category | GH / IGF-1 axis | GH / IGF-1 axis |
| Evidence level | Low | Low |
| Overall status | Not approved — research | Not approved — research (diagnostic use in Japan) |
| FDA | Not approved | Not approved |
| EMA | Not approved | Not approved |
| WADA | Prohibited — S2 | Prohibited — S2 |
| Mechanism studied | Ipamorelin → GHS-R1a → Selective GH release → IGF-1 | GHRP-2 → GHS-R1a → Pituitary GH release → IGF-1 |
| Molecular weight | 711.9 g/mol | 818 g/mol |
| Sizes in stock | 5mg, 10mg | Not currently listed |
Where the research overlaps
Both compounds are studied within GH Axis research. Ipamorelin is classed as selective gh secretagogue, while GHRP-2 is gh secretagogue. Evidence is rated low for Ipamorelin and low for GHRP-2.
For a full write-up, read CJC-1295 vs Ipamorelin: GH Secretagogues Compared.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.